List of Vimpat drug patents

Vimpat is owned by Ucb Inc.

Vimpat contains Lacosamide.

Vimpat has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Vimpat are:

  • USRE38551

Vimpat was authorised for market use on 28 October, 2008.

Vimpat is available in solution;intravenous dosage forms.

Vimpat can be used as method of treating partial onset seizures in patients 4 years of age and older; method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; method of use for treatment of partial-onset seizures in patients 4 years of age and older; method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

The generics of Vimpat are possible to be released after 14 October, 2024.

VIMPAT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551 UCB INC Anticonvulsant enantiomeric amino acid derivatives
Mar, 2022

(1 year, 5 days ago)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 16, 2023
New Patient Population (NPP) Oct 14, 2024

Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 28 October, 2008

Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VIMPAT before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in